All lobbying filings

Forbes-Tate

Forbes-Tate filed a Q4 report for Alexion Pharmaceuticals, Inc. on January 17, 2026, reporting $50,000 in lobbying income.

Lobbying for Alexion Pharmaceuticals, Inc. · Biopharmaceutical Company

As filed: FORBES-TATE for ALEXION PHARMACEUTICALS, INC.

All filings by Forbes-Tate · Everything Alexion Pharmaceuticals, Inc. has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 17, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to orphan drug tax credit; Issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to orphan drugs under the Drug Price Negotiation Program.

Medicare/Medicaid

Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.